L-Arginine and Reduced Timed Up and Go Test Time

• Efficacy of l-Arginine treatment in patients with HTLV-1-associated neurological disease.

  • 2022-12-22
  • Clinical Trial · n = 20
  • Annals of clinical and translational neurology 10(2)
  • • Satoshi Nozuma
    • Eiji Matsuura
    • Yuichi Tashiro
    • Ryusei Nagata
    • Masahiro Ando
    • Yu Hiramatsu
    • Yujiro Higuchi
    • Yusuke Sakiyama
    • Akihiro Hashiguchi
    • Kumiko Michizono
    • Keiko Higashi
    • Toshio Matsuzaki
    • Daisuke Kodama
    • Masakazu Tanaka
    • Yoshihisa Yamano
    • Takashi Moritoyo
    • Ryuji Kubota
    • Hiroshi Takashima

  • PubMed: 36547017
  • DOI: 10.1002/acn3.51715

  3 Insights on

  • Reduced Timed Up and Go Test Time

  • Moderate evidence
  • Clinical

  Significant improvements were also observed in selected secondary endpoints, including in TUGT time (-9.1%, 95% CI -15.5% to -2.7%; P < 0.01)

  Effect

  Beneficial

  Effect size

  Small

  Significant

  Yes

  Dose

  20 g/day